LMP7/PSMB8 Antibody (832913) [Alexa Fluor® 700]

• Reactivity: Hu
• Applications: WB
• Clone: 832913
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 700

LMP7/PSMB8 Antibody (832913) [Alexa Fluor® 700] Summary

• Immunogen: E. coli-derived recombinant human LMP7/PSMB8
  Thr73-Gln276
  Accession # P28062
• Specificity: Detects human LMP7/PSMB8 in ELISAs. In direct ELISAs, no cross-reactivity with recombinant human LMPX/PSMB5 is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for LMP7/PSMB8 Antibody (832913) [Alexa Fluor® 700]

• ALDD
• beta5i
• D6S216E
• EC 3.4.25.1
• JMP
• LMP7
• LMP7MGC1491
• Low molecular mass protein 7
• low molecular weight protein 7
• Macropain subunit C13
• Multicatalytic endopeptidase complex subunit C13
• NKJO
• protease component C13
• proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctionalpeptidase 7)
• proteasome catalytic subunit 3i
• Proteasome Component C13
• proteasome subunit beta 5i
• proteasome subunit beta type-8
• Proteasome subunit beta-5i
• Proteasome Subunit Y2
• proteasome-related gene 7
• PSMB5i
• PSMB5iD6S216
• PSMB8
• Really interesting new gene 10 protein
• RING10
• RING10proteasome (prosome, macropain) subunit, beta type, 8 (large multifunctionalprotease 7)
• Y2

Background

PSMB8 (Proteasome Subunit beta type-8; Also beta 5i, RING10/Y2 and LMP7) is a 23-24 kDa member of the peptidase T1B family of molecules. It is expressed both constitutively and inducibly by IFN-gamma in a wide variety of cells, including immature dendritic cells, preadipocytes, CD4⁺ T cells and monocytes. LMP7 is a subunit of the 700 kDa, 20S proteasome catalytic complex, a dynamic intracellular structure that participates in ATP-dependent proteolytic activity. LMP7 qualifies as a beta -type, i (immuno)-type proteasome, meaning it both plays a chymotrypsin-like role in the turnover of proteins and is found in cytokine-responsive cells. The peptides generated through LMP7 activity are presented as antigens by MHC-I molecules. LMP7 activity is dependent upon the removal of the LMP7 precursor prosequence, an action that exposes a critical internal Thr residue. Human LMP7 is synthesized as a 28-29 kDa, 276 amino acid (aa) proprecursor. It contains a 72 aa autocleavable propeptide plus a 204 aa mature region. There is one alternative splice form that shows a 45 aa substitution for aa 1-49. This isoform does not appear to participate in formation of a proteosome. Over aa 73-276, human LMP7 shares 92% aa sequence identity with mouse LMP7.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P28062()